Tiziana Life Sciences says it has developed an investigational new technology that it hopes will ultimately be used to treat COVID-19 infections. This technology enables direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebuliser.

Development of this novel technology is a step forward toward expediting development of TZLS-501, a fully-human anti-IL6R mAb for treatment of patients infected with COVID-19. Source: Pharmatimes 9/4/2020